Is the transdermal combined estrogen‑progestin contraceptive patch suitable for a 35‑year‑old woman with a BMI of 45 kg/m²?

The Birth Control Patch is NOT Recommended for a 35-Year-Old Woman with BMI 45

For this patient, I strongly recommend progestin-only contraceptive methods (pills, implants, or IUDs) instead of the combined estrogen-progestin patch, due to significantly elevated thrombotic risk and uncertain efficacy at this BMI.

Critical Safety Concerns

Thrombotic Risk is Substantially Elevated

Your patient faces a dangerous combination of risk factors:

• Obesity alone (BMI >30) increases VTE risk 3.7-fold compared to normal weight women 1
• Combined hormonal contraceptives in obese women increase MI risk to 5.1 (compared to 3.4 for obesity alone) 1
• These risks are additive, not synergistic – but the absolute risk remains concerning 1

At age 35, she is at the upper threshold where guidelines state benefits outweigh risks for combined hormonal contraception in obese women without other cardiovascular risk factors 1. However, this guidance applies to BMI ≥30 kg/m², and there are almost no data on women with BMI above 35 kg/m² 1.

Efficacy is Questionable at This Weight

The evidence regarding patch effectiveness at high BMI is concerning:

• Body weight ≥90 kg (198 lbs) is associated with lower efficacy of the original norelgestromin/ethinyl estradiol patch 2, 3
• Studies found a significant association between body weight and pregnancy risk in patch users 1
• The newer low-dose levonorgestrel/ethinyl estradiol patch (Twirla®) is FDA-approved only for women with BMI <30 kg/m² 4

At BMI 45, your patient likely weighs well over 90 kg, placing her in the higher-risk category for contraceptive failure.

Superior Alternative: Progestin-Only Methods

Progestin-only contraceptives can be used without restriction in obese women 1:

• No increased VTE risk compared to combined hormonal methods
• No data suggesting reduced efficacy in obesity
• Levonorgestrel IUD, etonogestrel implant, or progestin-only pills are all excellent options

Specific Considerations:

• Etonogestrel implant: Consider replacement at 2 years instead of 3 years in overweight women, though pregnancy rates remain low 1
• DMPA injection: Avoid in this patient as it can cause weight gain in obese women 1
• Levonorgestrel IUD: No restrictions, highly effective regardless of weight 1

Clinical Decision Algorithm

For a 35-year-old woman with BMI 45:

1. Screen for additional cardiovascular risk factors (hypertension, diabetes, smoking, hyperlipidemia)
2. If ANY additional risk factors present: Combined hormonal contraception is contraindicated
3. If no other risk factors: Combined hormonal methods are still inadvisable due to:
   • Lack of safety data at BMI >35
   • Documented reduced patch efficacy at high body weight
   • Safer alternatives available
4. Recommend progestin-only methods as first-line

Common Pitfalls to Avoid

• Don't extrapolate data from BMI 30-35 to BMI 45 – the evidence gap is real and clinically significant
• Don't assume all patches are equivalent – newer patches have explicit BMI restrictions
• Don't overlook that this patient is 35 years old – the age threshold where combined hormonal contraception becomes relatively contraindicated in the presence of other risk factors

The French Society of Endocrinology guidelines explicitly state that for women under 35 years with no cardiovascular risk factors and BMI ≥30, benefits outweigh risks 1. Your patient is exactly at this age threshold, making the risk-benefit calculation even less favorable.